We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Orphan without a home

15 Jul 2013 By Neil Unmack

The pharma giant is eyeing a $20 billion plus bid for Alexion, Reuters says. The U.S. biotech group’s lucrative line in rare “orphan” drugs could help Roche diversify after recent setbacks. But the mooted price isn’t cheap, and orphan drugs’ blessed protected status may not last.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)